ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer
Journal of Cell Science · 15.09.2023 · 136 (18)
DOI: 10.1242/jcs.260964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, online erschienen am 18.09.2023. Verfasst von Haiqin Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, 250013 Shandong, P. R. China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is the most aggressive and poorly treated subtype of breast cancer. Identifying novel drivers and mechanisms for tumor progression is essential for precise targeted therapy of TNBC. Immunoglobulin-like transcript 4 (ILT4; also known as LILRB2) is a classic myeloid suppressor for their activation and immune response. Our recent results found that ILT4 is also highly expressed in lung cancer cells, where it has a role in promoting immune evasion and thus tumor formation. However, the expression and function of ILT4 in breast cancer remains elusive. Here, using our patient cohort and public database analysis, we found that TNBC displayed the most abundant ILT4 expression among all breast cancer subtypes. Functionally, enriched ILT4 promoted TNBC cell proliferation, migration and invasion in vitro, as well as tumor growth and metastasis in vivo. Further mechanistic analysis revealed that ILT4 reprogrammed aerobic glycolysis of tumor cells via AKT-mTOR signaling-mediated glucose transporter 3 (GLUT3; also known as SLC2A3) and pyruvate kinase muscle 2 (PKM2, an isoform encoded by PKM) overexpression. ILT4 inhibition in TNBC reduced tumor progression and GLUT3 and PKM2 expression in vivo. Our study identified a novel driver for TNBC progression and proposed a promising strategy to combat TNBC by targeting ILT4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Jinan Central Hospital, Shandong University, Jinan, 250013 Shandong, P. R. China.
- Department of Oncology, Central hospital affiliated to Shandong First Medical University, Jinan, 250013 Shandong, P. R. China.
- Research Center of Translational Medicine, Laboratory Animal Center, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013 Shandong, P. R. China.
- Department of Thoracic Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Shandong First Medical University, Jinan, 250117 Shandong, P. R. China.
- Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013 Shandong, P. R. China.
- Phase I Clinical Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, 250117 Shandong, P. R. China.
ORCID-Profile: Haiqin Zhang, Aiqin Gao, Qiaohong Liu, Fang Zhang, Shuyun Wang, Xiaozheng Chen, Wenjing Shi, Ye Zhang, Qian Liu, Yan Zheng, Yuping Sun
Förderung
- China Postdoctoral Science Foundation
- Natural Science Foundation of Shandong Province
- National Natural Science Foundation of China
- Jinan Science and Technology Development Program
- Science and Technology Planning Project of Jinan Health Commission
Zitieren
APA
Zhang, H., Gao, A., Liu, Q., Zhang, F., Wang, S., Chen, X., Shi, W., Zhang, Y., Liu, Q., Zheng, Y., & Sun, Y. (2023). ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer. Journal of Cell Science, 136(18). https://doi.org/10.1242/jcs.260964
Vancouver
Zhang H, Gao A, Liu Q, Zhang F, Wang S, Chen X, et al. ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer. Journal of Cell Science. 2023;136(18). doi:10.1242/jcs.260964
BibTeX
@article{Zhang2023,
author = {Zhang, Haiqin and Gao, Aiqin and Liu, Qiaohong and Zhang, Fang and Wang, Shuyun and Chen, Xiaozheng and Shi, Wenjing and Zhang, Ye and Liu, Qian and Zheng, Yan and Sun, Yuping},
title = {ILT4 reprograms glucose metabolism to promote tumor progression in triple-negative breast cancer},
journal = {Journal of Cell Science},
year = {2023},
volume = {136},
number = {18},
doi = {10.1242/jcs.260964}
}
EUVIMED